Jon Gambill, PA
Medical · Canyonville, ORNPI 1073586319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.
Across 119 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$499
- AbbVie$354
- AstraZeneca$201
- Johnson & Johnson$196
- GSK$189
- Kowa Pharmaceuticals America, Inc.$76
- plus $648 from 20 others
What the payments were for
- Food & beverage$2,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $499 |
| AbbVie | 21 | $354 |
| AstraZeneca | 13 | $201 |
| Johnson & Johnson | 13 | $196 |
| GSK | 8 | $189 |
| Kowa Pharmaceuticals America, Inc. | 4 | $76 |
| Novo Nordisk | 4 | $73 |
| Mylan Specialty L.p. | 3 | $68 |
| Pfizer | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $41 |
| Edwards Lifesciences | 2 | $36 |
| Alkermes, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Novartis | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
How this compares
$2,162 in reported general payments places this provider in the 85th percentile of 364 medical providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 41 | $46,029 |
| FarxigaDapagliflozin Propanediol | 62 | $45,453 |
| JardianceEmpagliflozin | 48 | $43,991 |
| OzempicSemaglutide | 31 | $37,744 |
| Repatha SureclickEvolocumab | 25 | $23,720 |
| EliquisApixaban | 27 | $23,014 |
| MounjaroTirzepatide | 13 | $13,349 |
| TrulicityDulaglutide | 12 | $11,256 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,644 |
| DapagliflozinDapagliflozin Propanediol | 16 | $6,577 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 12 | $6,496 |
| Telmisartan | 169 | $4,516 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 268 | $3,961 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $2,844 |
| Potassium Chloride | 149 | $2,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $196 | $46,02941 claims |
| AstraZenecaFarxiga | $201 | $45,45362 claims |
| Boehringer IngelheimJardiance | $41 | $43,99148 claims |
| Novo NordiskOzempic | $73 | $37,74431 claims |
| Lilly USA, LLCMounjaro, Trulicity | $30 | $24,60525 claims |
| PfizerEliquis | $67 | $23,01427 claims |
| AbbVieSynthroid | $354 | $67022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 364 medical providers in Oregon.
Other medical in Canyonville
- Mark DavisLake Oswego$12K
- Britt BennPortland$11K
- Benjamin WillettSalem$11K
- Jeffrey RennaSalem$9K
- Christy SnoSpringfield$8K
- Erica BallardPortland$8K
- Nicole WydraCorvallis$8K
- Caitlyn EricksonHillsboro$6K
- Brolin JohnsonSalem$6K
- Maci PfaffenbergerGresham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.